BJBjoern Jacobsen

Bjoern Jacobsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bjoern Jacobsen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Adam Hey

    Novartis Pharma AG, Basel, Switzerland

    1 shared publication
  • Andreas Brink

    Department of Toxicology, University of Würzburg, Versbacher Strasse 9, 97078 Würzburg, Germany

    1 shared publication
  • Andres Eskjær Jensen

    Ellegaard Göttingen Minipigs A/S, Soroe Landevej 302, 4261, Dalmose, Denmark

    1 shared publication
  • Anna Engstrom

    Genentech Inc, Translational Safety, South San Francisco, CA, USA

    1 shared publication
  • Anne Eichinger-Chapelon

    Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland

    1 shared publication
  • Annika Herrmann

    Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (SL, BJ, MBO, AH, SK)

    1 shared publication

Latest Publications

  • Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeutics

    by Anna Engstrom, Tine Dahlbaek Hannibal, Jerome Egli, Beatrice Gauthier, Mikkel Lykke Krarup, Daniela Gallo, Andres Eskjær Jensen, Steven Van Cruchten, Steven Bulera, Miranda Cornet, et al.


  • Drug-induced Obstructive and Retrograde Nephropathy Associated with α2u-globulin in Male Rats

    by Björn Jacobsen, Christian Freichel, Anne Eichinger-Chapelon, Andreas Brink, Jean-Christophe Hoflack, Mudher Albassam, Barbara Lenz

    The chemically induced accumulation of α2u-globulin protein in male rats causes specific renal lesions and subsequent nephropathy. Herein, we report additional parallel findings in the kidney of male rats consistent with obstructive and retrograde nephropathy. Kidney and urinary bladder samples were evaluated from Wistar rats treated with RG7129 for 2 week and 8 week and from an 8-week mechanistic study using females, intact and castrated males. Histopathological findings were present in intact males in all studies, including hyaline droplet accumulation and granular casts consistent with α2u-globulin nephropathy. In addition, tubular degeneration and regeneration, tubular changes extending from papilla to cortex, tubular dilation, and interstitial and luminal inflammation were observed consistent with retrograde and obstructive nephropathy. Renal and urinary lesions and their severity increased in a time- and dose-dependent manner. Urinalysis findings, including increases in leukocytes, protein, and in kidney biomarkers, kidney injury molecule 1 and clusterin, were present only in intact males. No treatment-related changes were observed in female rats or in castrated males. These results indicate that RG7129 induces α2u-globulin nephropathy, associated with retrograde and obstructive nephropathy secondary to precipitation in intact male rats only, constituting a species- and sex-specific syndrome that is not expected to occur in humans or other species.


  • Distribution of FcRn Across Species and Tissues

    by Sari Latvala, Bjoern Jacobsen, Michael B. Otteneder, Annika Herrmann, Sven Kronenberg

    The neonatal Fc receptor (FcRn) is a major histocompatibility complex class I type molecule that binds to, transports, and recycles immunoglobulin G (IgG) and albumin, thereby protecting them from lysosomal degradation. Therefore, besides the knowledge of FcRn affinity, FcRn protein expression is critical in understanding the pharmacokinetic behavior of Fc-containing biotherapeutics such as monoclonal antibodies. The goal of this investigation was to achieve for the first time a comparative assessment of FcRn distribution across a variety of tissues and species. FcRn was mapped in about 20 tissues including placenta from human and the most frequently used species in non-clinical safety testing of monoclonal antibodies (mouse, rat, cynomolgus monkey). In addition, the FcRn expression pattern was characterized in two humanized transgenic mouse lines (Tg32 and Tg276) expressing human FcRn under different promoters, and in the severe combined immunodeficient (SCID) mouse. Consecutive sections were stained with specific markers, namely, anti-CD68 for macrophages and anti–von Willebrand Factor for endothelial cells. Overall, the FcRn expression pattern was comparable across species and tissues with consistent expression of FcRn in endothelial cells and interstitial macrophages, Kupffer cells, alveolar macrophages, enterocytes, and choroid plexus epithelium. The human FcRn transgenic mouse Tg276 showed a different and much more widespread staining pattern of FcRn. In addition, immunodeficiency and lack of IgG in SCID mice had no negative effect on FcRn expression compared with wild-type mice.


  • Open Access

    FcRn Expression on Placenta and Fetal Jejunum during Early, Mid-, and Late Gestation in Minipigs

    by Björn Jacobsen, Marilyn Hill, Lucie Reynaud, Adam Hey, Paul Barrow

    Developmental toxicity testing of therapeutic antibodies is most often conducted in nonhuman primates owing to lack of cross-reactivity in other species. Minipigs may show cross-reactivity for some humanized antibodies but have not been used for developmental toxicity testing due to an assumed lack of embryo-fetal exposure. Unlike in humans, maternal IgGs do not cross the porcine placenta to reach the fetus. Some humanized IgGs, however, have a higher affinity for the neonatal Fc receptor (FcRn) and are more likely than endogenous antibodies to cross the placenta of animals. The major site of prenatal IgG transfer is the placenta, though FcRn in fetal intestine could also uptake maternal IgGs from swallowed amniotic fluid. Using immunohistochemistry and in situ hybridization in this experiment, FcRn was found in minipig placenta and fetal intestine during early, mid-, and late gestation. To date, however, fetal exposure to maternally administered IgGs has never been demonstrated in the minipig.